Male breast cancer (MBC) is rare and remains largely managed using knowledge derived from female breast cancer. Here, we generated a multiplatform single-cell and spatial transcriptomic atlas integrating scRNA-seq, SeekSpace, Visium HD, Xenium In Situ, and multiplex immunohistochemistry data from male and female breast...
Hao-Yuan Shi, Xiu-Li Zhang, Shou-Liang Cai et al.· Science Advances· 0 citations
Iza-bren significantly improved progression-free survival versus chemotherapy, and median progression-free survival assessed by Blinded Independent Central Review was 8·2 months (95% CI 6·9-8·6) versus 4·0 months (2·9-4·3; HR 0·41 [95% CI 0·33-0·53).
B. Lan, Ye-Hui Shi, Xi-Ying Shao et al.· The Lancet· 0 citations
This study identifies ZUP1 as a potential oncogenic factor and a robust independent prognostic biomarker in breast cancer and suggests that ZUP1 is a novel multifaceted biomarker with significant implications for personalized treatment strategies in breast cancer.